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Abstract
Background: This study aimed to measure the gait abnormalities in GRMD (Golden retriever muscular dystrophy)
dogs during growth and disease progression using an ambulatory gait analyzer (3D-accelerometers) as a possible
tool to assess the effects of a therapeutic intervention.
Methods: Six healthy and twelve GRMD dogs were evaluated twice monthly, from the age of two to nine months.
The evolution of each gait variable previously shown to be modified in control and dystrophin-deficient adults was
assessed using two-ways variance analysis (age, clinical status) with repeated measurements. A principal
component analysis (PCA) was applied to perfect multivariate data interpretation.
Results: Speed, stride length, total power and force significantly already decreased (p < 0.01) at the age of 2
months. The other gait variables (stride frequency, relative power distributions along the three axes) became
modified at later stages. Using the PCA analysis, a global gait index taking into account the main gait variables was
calculated, and was also consistent to detect the early changes in the GRMD gait patterns, as well as the
progressive degradation of gait quality.
Conclusion: The gait variables measured by the accelerometers were sensitive to early detect and follow the gait
disorders and mirrored the heterogeneity of clinical presentations, giving sense to monitor gait in GRMD dogs
during progression of the disease and pre-clinical therapeutic trials.
Background
Duchenne muscular dystrophy (DMD), a still incurable
severe and generalized muscle disease in man, repre-
sents a therapeutic challenge because of the numerous
obstacles it presents for systemic gene, cell or pharma-
cological therapies. Several of these issues, such as effi-
cacy of studied drugs, or locoregional or systemic
medication pathways, can be assessed in the dystrophin-
deficient dog, a large animal model which mimics the
human disease in many points, better than other animal
models [1].
During pre-clinical trials, to assess a functional effect,
these canine patients must undergo a clinical follow-up
encompassing a qualitative and quantitative evaluation
of their impaired functions, particularly the gait.
Recently, two studies including ours have focused on
gait analysis in adult dogs suffering from Golden retrie-
ver muscular dystrophy (GRMD), using two different
tools [2,3]. Both studies have demonstrated that GRMD
dogs walk slower than healthy controls, and that several
specific gait parameters were altered. The kinematic
analysis of the hind limb has shown an increase of the
stifle joint extension, and a decrease of the hock joint
flexion, this last joint being moreover less mobile than
in control dogs [2]. The accelerometry study we have
conducted has shown less regular and powerful accel-
erations, a decrease of the stride length and frequency,
and a redistribution of the power from the cranio-caudal
to the medio-lateral axis [3].
These studies have demonstrated that gait analysis is
feasible and repeatable in adult GRMD dogs and that
these animals exhibit quantifiable gait impairments.
However, the majority of the treatments that are tested
in GRMD dogs are administered during the first months
of life, at a period when the morphological changes due
to growth as well as the clinical evolution rate are
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characterize the dynamic evolution of the gait para-
meters tested by an ambulatory gait analysis system
based on 3D-accelerometers, in order to delineate the
disease progression in the GRMD model over time. We
aimed to address the question if the gait variables are
able to reflect disease evolution according to the pre-
vious results obtained in control and dystrophin-defi-
cient adults [3]. Another question was to determine if
the gait analysis was able to quantitatively describe the
well-known heterogeneity of the model [1,7]. These
points represent pre-requisites for the use of this
method in pre-clinical trials. This is the first longitudi-
nal study on gait analysis in growing GRMD dogs, and
the first study using an ambulatory gait analysis system
to monitor the canine gait evolution, during growth and
disease progression.
Methods
Subjects
All procedures were carried out in accordance with the
Guide of the Care and the Use of Laboratory Animals,
and approved by the Ethical Committee of the National
Veterinary School of Alfort.
Six healthy golden retriever and twelve GRMD male
dogs were included in the study. All the dogs were
housed in the same facilities. The healthy dogs were lit-
termates of some GRMD dogs of the study. Two of
them (Ckan and Cbof) have taken part in the first study
at an adult age [3]. The dogs were genotyped as pre-
viously described [8], before the age of 2 months, and
GRMD dogs were randomly selected among the new-
borns of the French GRMD colony. Each GRMD dog
underwent the clinical score evaluation monthly during
the whole study period, using our previously described
grid [9]. In our grading system, the more the dog is
affected, the higher the score is. No GRMD dog had
taken part in the previous study on adult dogs [3].
Materials
The 3-dimensional accelerometer recorder used in this
s t u d yw a saL o c o m e t r i x
® gait analysis system, composed
of 3 orthogonally-positioned accelerometers, to allow the
recording of the accelerationsa l o n gt h ed o r s o - v e n t r a l ,
cranio-caudal and medio-lateral axes of the dogs, as pre-
viously described [3]. The measurement range of the
accelerometer was ± 2 g, with a resolution of 0.001 g.
The signal was recorded at a sampling rate of 100 Hz and
anti-aliasing filter was used with a cut off set at 50 Hz.
Gait testing
As previously described [3], dogs were carried from the
kennel to a 45 metre-long corridor located close to the
laboratory facilities. The belt in which the
accelerometric device was inserted was fastened around
the thorax of the dog, so that the device was placed
under the sternum, near to the centre of gravity at rest.
The study design encompassed 15 tests per animal, at
a frequency of one test session twice monthly, from the
age of two months, that can be considered as the onset
of motor clinical signs in animals surviving to the neo-
natal form, to nine months, i.e. during the period of
growth and of disease progression [1]. A few minutes
before the first test at two months, the young puppies
were familiarized to the corridor and to the belt. The
height of each dog on the back, immediately caudally to
the shoulders, defining the height at withers (HW), was
measured at the end of each test. All the tests were
performed by the same operator (IB).The test was per-
formed as previously described, encouraging the dog to
w a l ko rr u na th i sp r e f e r r e dg a i ta n ds p e e d ,a n dt i m i n g
him over five metres for each used gait [3]. The free
ambulation choice has been previously argued in studies
on GRMD locomotion [2,3], and will be further
discussed.
Data analysis
The analysis of the acceleration curves was performed
using the Equimetrix
® software for quadrupedal gait
analysis. Every sequence of 10 seconds of steady state
locomotion was analysed, whatever the type of gait,
which was easily identifiable on the dorso-ventral accel-
eration curves (Additional file 1). The speed measured
during the test for each given type of gait was used for
the analysis. The regularity, an index quantifying the
similarity of dorso-ventral accelerations over successive
strides, was used as an indicator of quality of gait, in
order to select the gait the dog would be more comfor-
table with. Thus, when more than one type of gait
(walk, trot or gallop) was analyzed during a test, the
type of gait for which the regularity score was the best
was selected.
The studied variables were described in details in pre-
vious publications [3,10]. Except for the speed, which
was measured by the operator during the test, over 5
metres of steady gait, they were all calculated by the
adapted software Equimetrix
® for quadrupedal locomo-
tion analysis, as follows:
￿ The stride frequency (/s), calculated as a quarter
(walk) or a half (trot, gallop) of the fundamental fre-
quency, using Fast Fourier Transform (FFT).
￿ The stride length (m), calculated by dividing the
speed by the stride frequency.
￿ The stride regularity (dimensionless), calculated by
adding two coefficients of correlation (correlation of
acceleration within a stride, and between strides),
obtained by calculating the autocorrelation function
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these two coefficients was multiplied by 100 and
normalized by a Z transform.
￿ The total power of accelerations (W/kg), calculated
by adding the powers calculated in the three axes.
The power in each direction was computed as the
integral of the power spectrum obtained by the FFT
from the raw acceleration signal.
￿ The relative components of the total power along
the three axes (%), calculated by dividing the cranio-
caudal, dorso-ventral or medio-lateral power by the
total power.
￿ The relative force index (N/kg), calculated by
dividing the total power by the speed, in order to
avoid variations due to different speeds, and/or to
different types of gait. As 1 W = 1 Nm.s
-1,t h e
resulting ratio (W.kg
-1/m.s
-1) was expressed in N/kg,
and named relative force index.
The speed and the stride length were normalized by
t h eh e i g h ta tw i t h e r s( H W ) ,i no r d e rt oa v o i dt h ee f f e c t
of size on these variables.
Statistical analysis
For each variable, a repeated measures analysis of var-
iance, with age as a within effect factor and group
(GRMD vs. Healthy) as a between effect factor was used
in order to assess:
￿ The effect of age on the evolution of gait variables
in Healthy dogs
￿ The effect of age and disease progression on the
evolution of gait variables in GRMD dogs
￿ The impact of the disease on the evolution of gait
variables
￿ The differences between the two groups
AP e a r s o n ’s correlation coefficient was calculated in
order to study the correlations between variables, and
mainly between the clinical score and the gait variables
in GRMD dogs.
Finally, in order to summarize the results we proposed
a graphic representation of the gait evolution of the
dogs. The individuals were projected, as supplementary
observations, on the reference PCA plane that we pre-
viously defined in [3], using eight healthy and 11 GRMD
adult dogs, and the seven following variables: stride
length/HW, stride frequency, total power, medio-lateral,
cranio-caudal, dorso-ventral parts of the total power,
and regularity. For each age point, the Euclidean dis-
tance in the seven-dimensional space between each
GRMD dog and the centre of gravity of the six age-
matched healthy controls was calculated in order to
assess if this distance could be used as an overall “gait
score” variable, as previously described by Schutte et al.
[11]. This distance was also submitted to the repeated
measures ANOVA, and a Pearson’s correlation coeffi-
cient to the clinical score was calculated.
The level of statistical significance was set at p = 0.01
for all the tests.
Results
Test compliance
All the planned test sessions could be performed in the
six healthy dogs (Table 1). However, at the age of 2.5
months, four of them were too unruly and their accel-
eration curves too unstable to be analyzed. Therefore,
no comparison between both groups was possible at this
time point. The preferential gait was the trot at each age
point, and for all the dogs, except for three of them at 2
months, and for one of them at 3 months, who per-
formed a rotary gallop.
Five of the 12 GRMD dogs died before the age of nine
months and therefore could not perform the 15 tests
(see Table 1). Among these five dogs, three (Dchou,
Dfois and Dsir) were euthanized due to a complete loss
of locomotion and permanent recumbency, at the age of
four (Dchou) and six (Dfois and Dsir) months. Another
dog, Dmo, died from digestive complication of the dis-
ease at five months. The last dog, Dlire, developed
severe aspiration pneumonia at nine months, and could
therefore not perform the last test because of pro-
nounced dyspnea; he died the following day.
Among the seven dogs who completed all the tests, six
(all except Dbrouille) were successfully treated for at
least one episode of aspiration pneumonia, and four (Dk,
Didon, Dlice and Dmon) got a gastrostomy tube when
they became unable to feed by themselves and needed a
fluid correction to maintain a normal hydration state.
The GRMD dogs employed three different types of
gait: the so-called “bunny hopping” bound gallop, the
trot and the walk. The different types of gait were easily
identifiable on the dorso-ventral acceleration curves
(Additional file 1).
The main statistical results are presented in Table 2,
and details regarding each age point are summarized in
Additional file 2. Figure 1 offers a graphic representation
of the individual evolutions of GRMD dogs with age, in
comparison to the mean ± 1 SD of healthy controls. A
± 1 SD range was chosen because the variables did not
always follow a normal distribution, giving poor sense to
a ± 2 SD range representation.
Evolution of the variables with age in healthy dogs
The six healthy dogs were shown to walk quicker with
age (p < 0.0001) and to increase their stride length (p <
0.0001). Speed and stride length were found significantly
correlated with height at withers (respective Pearson’s
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n o r m a l i z e db yt h eh e i g h ta tw i t h e r s ,n oa g ee f f e c to n
the stride length was identified anymore, whereas the
speed was shown to decrease with age (p = 0.0024),
probably due to a decrease of the stride frequency (p <
0.0001). The medio-lateral part of the power decreased
with age (p < 0.01). No significant age effect was shown
for the other variables (i.e. the total power, the cranio-
caudal and the dorso-ventral part of the power, the
force and the regularity).
Table 1 Animals included in the study
Age point (months)
2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9
Healthy
Ckan T T T T T T na TTT na TTT T
Cbof RG T T T T T na TTT na TTT T
Dclick T na T TTTTTTTTT T T T
Dclack RG na T TTTTT na T T TTT T
Dzer T na T TTTTTTTTT T T T
Dzastre RG na R G TTTTTTTTT T T T
GRMD
Dchou TTW W Loss of locomotion
Dmo BG BG BG BG na BG Death
Dfois TTTTWWW Loss of locomotion
Dsir T na TTTWW Loss of locomotion
Dlire BG BG BG T T BG T T T T T T W T Death
Dlice T B GB GB GB G na TTTTT W T T W
Dluge T T BG BG BG BG BG T BG BG W T T T BG
Dk BG T BG W BG BG BG BG BG T BG W W W W
Dbrouille T T T TTTTTTTTT T T T
Dmon B G T B G B G TTTWTTTT W na W
Dalton BG na T TTTTTTTTT T T T
Didon TB G B G B GB GB GB GB GB GB GB GWW B G B G
The six healthy and 12 GRMD dogs included in the study are summarized in this table, as well as the significant clinical events, i.e. those which have led to a
premature end of the study in some GRMD dogs. The symbol of each GRMD dog, which is used in the figures, is mentioned beside his name. For each age point
and each animal, if the test was successful, the most regular gait, which was selected for the analysis, is mentioned using the following letters: W (walk), T (trot),
RG (rotary gallop), BG (bound gallop). The mention na means that the test was not analysable.
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From the age of 2 months, the gait of GRMD dogs was
shown to be significantly (p < 0.001) slower than the
gait of healthy dogs, even when the measured speed was
normalized by the height at withers (p < 0.01). No age
effect on speed could be identified in GRMD dogs,
while this variable was found to increase in growing
healthy dogs. However, when normalized by the height
at withers, the speed significantly decreased with age (p
< 0.01) in GRMD dogs.
In the same way, the stride length was already signifi-
cantly lower in GRMD dogs at the age of 2 months (p <
0.0001), even normalized by the height at withers (p <
0.0001). As for the speed, no age effect on stride length
was demonstrated, whereas growing healthy dogs
increased their stride length. No age effect was either
identified on this variable normalized by the height at
withers. However, considering the individual evolutions,
it appeared that some dogs tended to decrease their
stride length, while others tended to maintain or to
increase it.
This inter-individual variability was also striking for
the stride frequency parameter. Indeed, some dogs
which were able to use a regular typical “bunny
hopping” bound gallop gait until a late stage, maintained
stride frequency values above those measured in healthy
animals, whereas dogs which had switched to trot or
walk did less frequent strides. More generally, the low-
ered stride frequency was found to be a late modifica-
tion of gait (significant decrease from the age of 7.5
months, p < 0.0001 at this time point). Relative to
healthy dogs, GRMD dogs tended to decrease their
stride frequency with age, but not significantly (p =
0.017).
Conversely, but similarly to speed and stride length,
the total power of the gait was significantly decreased as
early as at 2 months of age (p < 0.01). No age effect on
the total power evolution in the GRMD population was
highlighted, probably due to individual variations in
diverging directions.
The relative force index, calculated by dividing the
total power by the speed, was shown to be significantly
different from the age of 3 months (p < 0.0001), and to
decrease with age (p < 0.01). A GRMD dog, Dlice, had a
very high force value at 2 months, resulting from one of
the best power values of the GRMD group, and from a
low speed, this puppy being the smallest of the study at
two months.
Table 2 Main results of the statistical analyses
Speed
(m/s)
Speed/
HW (/s)
SL (m) SL/HW SF (/s) TP (W/
kg)
Force
(N/kg)
CCP/TP
(%)
DVP/TP
(%)
MLP/TP
(%)
Regularity Distance
Age
effect
Healthy p <
0.0001
(↗)
p=
0.0024 (↘)
p<
0.0001
(↗)
NS p <
0.0001
(↘)
NS NS NS NS p =
0.0089
(↘)
p = 0.0145
(↗)
p=
0.0068
(↘)
GRMD NS p =
0.0067 (↘)
NS NS p =
0.0350
(↘)
NS p =
0.0034
(↘)
NS NS NS NS NS
Group
effect
p<
0.0001
p=
0.0003
p=
0.0002
p=
0.0002
NS p <
0.0001
p=
0.0006
NS p =
0.0427
p=
0.0162
p = 0.0090 p <
0.0001
2
months
Healthy 1.77
(0.29)
5.68 (0.90) 0.61
(0.07)
1.97
(0.26)
2.89
(0.20)
81.5
(18.6)
53.2 (6.3) 44.0
(7.7)
40.3
(7.5)
15.8 (6.1) 197 (49) 1.14
(0.60)
GRMD 1.02
(0.24)
3.72 (1.04) 0.37
(0.09)
1.35
(0.27)
2.70
(0.70)
44.1
(19.2)
43.4
(20.7)
45.7
(9.9)
34.7
(10.7)
11.2
(13.1)
209 (56) 2.61
(0.73)
pp =
0.0010
p=
0.0054
p<
0.0001
p=
0.0001
NS p =
0.0017
NS NS NS NS NS p =
0.0031
9
months
Healthy 2.61
(0.18)
4.39 (0.26) 1.18
(0.03)
1.99
(0.06)
2.21
(0.14)
111.4
(16.3)
41.7 (2.6) 47.8
(4.8)
43.3
(3.9)
8.9 (3.5) 269 (44) 0.80
(0.24)
GRMD 0.88
(0.46)
1.66 (0.75) 0.49
(0.22)
0.92
(0.31)
1.77
(0.43)
20.8
(16.9)
20.4 (9.3) 44.7
(13.5)
29.4
(6.6)
23.8 (9.1) 225 (31) 3.7 (0.93)
pp <
0.0001
p<
0.0001
p<
0.0001
p<
0.0001
p=
0.0337
p<
0.0001
p=
0.0002
NS p =
0.0009
p=
0.0033
NS p <
0.0001
Correlation with
motor score
-0.4353 -0.6480 -0.6834 -0.5082 -0.5640 -0.5368 -0.3492 0.4454 0.6248
pp =
0.0002
p<
0.0001
NS p <
0.0001
p<
0.0001
p<
0.0001
p<
0.0001
p=
0.0030
NS p =
0.0001
NS p <
0.0001
For each variable, the age effect for each group is presented in the first row, as well as the group effect. The two following rows show the mean (SD) of healthy
dogs/the mean (SD) of GRMD dogs, just above the p value, for the two extreme age points (i.e. 2 and 9 months). The Pearson’s coefficient of correlation with the
motor score and associated p values are given in the last row. The data at each age point are given in Additional file 2 available online.
Abbreviations: HW: height at withers, SL: stride length, SF: stride frequency, TP: total power, CCP/TP: cranio-caudal part of the total power, DVP/TP; dorso-ventral
part of the total power, MLP/TP: medio-lateral part of the total power, Distance (PCA): distance from the centre of gravity of the healthy group on the principal
analysis component plane, NS: not significant.
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Figure 1 Evolution of the different gait variables with age . Each GRMD dog is represented using its own symbol (see table 1). The healthy
population is represented by a grey zone, covering the mean (grey line) ± 1 SD (black lines). A: evolution of the motor score in GRMD dogs; B:
evolution of the speed normalized by the height at withers (HW); C: evolution of the stride length normalized by the height at withers (HW); D:
evolution of the stride frequency; E: evolution of the total power; F: evolution of the force; G: evolution of the medio-lateral part of the power;
H: evolution of the regularity.
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axes was also shown to be modified in GRMD dogs. At
several time points from the age of 3.5 months and
until the age of 9 months, a decreased relative dorso-
ventral power was shown. The medio-lateral part of the
total power was shown to be increased from the age of
5.5 months (p < 0.01). The cranio-caudal part of the
power was not modified between 2 and 9 months of age.
The regularity index was significantly decreased only
at the 4.5 months time point (p < 0.01). No significant
age effect on the evolution of this variable was
demonstrated.
Significant correlations with the motor score were
found for 8 variables (see Table 2).
Figure 2 shows the course of healthy and GRMD
dogs on the principal component analysis (PCA) plane
at 2, 4, 6 and 9 months, and the evolution of the Eucli-
dean distance between the GRMD individuals and the
control population with age. The levels of statistical
significance of this global gait index are summarized in
Table 2. It has to be firstly underlined that the healthy
dogs progressively and nicely superimposed as supple-
mentary individuals to the healthy adult population of
the reference PCA plane defined in our previous study
[3]. If the distance of GRMD dogs from the healthy
group is already significantly increased at the age of 2
months, the graphic representation of the growing ani-
mals on the PCA plane demonstrated that the GRMD
population progressively moves towards the left side,
away from the healthy animals, essentially following
the component 1 axis, which is mainly explained by
t h es t r i d el e n g t ha n df r e q u e n c y ,t h et o t a lp o w e ra n d
the medio-lateral part of power. At the latest time
point, the GRMD dogs were superimposed to the adult
GRMD dogs scatter plot, regarding the first compo-
nent. Their localization along the component 2 axis
was however variable, more directed along the cranio-
caudal relative power vector than along the dorso-ven-
tral one. The graph showing the evolution of the dis-
tance between groups in relation with the age
illustrates the progressive separation of both popula-
tions, as well as the huge gait quality heterogeneity in
the GRMD population, using a quantitative condensed
variable calculated from seven accelerometric raw vari-
ables. Finally, this distance was found positively corre-
lated to the clinical motor score (R = 0.62, p < 0.0001).
However it was obviously able to better distinguish
between GRMD dogs: at the age of 9 months for
instance, all the GRMD dogs except Dbrouille were
found very close to each other using the motor score
(Figure 1), whereas a clear separation was identified
using the distance from the healthy population on the
PCA plane (Figure 2).
Discussion
This study has demonstrated the ability of 3D-accelero-
metry to early monitor the gait of GRMD dogs during
growth and disease progression. It is the first study
quantitatively describing sequential gait impairments in
this canine model of DMD.
Early modifications of GRMD dogs’ gait have been
highlighted, at a stage when the gait could appear nor-
mal to a non-experienced observer, attesting to the sen-
sitivity of the accelerometric method. Indeed as soon as
at the age of two months, a dramatic lack of power was
detected, resulting in a speed decrease, primarily
e x p l a i n e db yad r o pi ns t r i d el e n g t h .T h ed e c r e a s eo f
stride frequency was a later event, secondarily contribut-
ing to the reduction of speed. These patterns of evolu-
tion are very close to those already described in DMD
patients [12,13].
Whatever the age of the dogs, the total power of
GRMD dogs was shown to be strongly decreased, but
varied with age in its three-axial composition. The
decrease in total power was primarily harmonious
among the three axes. Then, the relative dorso-ventral
power dropped, followed by a later increase of the
medio-lateral part of power. This last event has been
described in adult GRMD dogs [3], but combined with a
decrease of the cranio-caudal part of power, which was
not present in growing puppies, even in 9 months-old
animals. Some of the growing GRMD dogs were exam-
ined at the age of 12 months, and this test showed that
within 3 months, the cranio-caudal relative power
dropped and the dorso-ventral one normalized (data not
shown). Briefly, during the first year of life of GRMD
dogs, the gait first becomes less bouncing, maybe as a
c o n s e q u e n c eo ft h ee a r l ym u s c l ew e a k n e s st os u p p o r t
weight, then waddling maybe reflecting contractures and
less balance, and finally less propelling and mobile.
One remarkable issue is the wide intra-individual var-
iations of some variables between fortnightly sessions. If
the repeatability between sessions has been demon-
strated for adult clinically stabilized GRMD dogs [3], the
same does obviously not hold true for clinically evolving
and growing animals. It may be assumed that these var-
iations are due to the fluctuating day-to-day general
shape of the diseased animals during their first months
of life. This inter-session variability also underlines the
necessity of a careful clinical follow-up of these dogs
and of frequent iterative examinations. The simplicity,
the lightness and non-invasivity of the accelerometric
device allow the repetition of tests over a short period
of time.
A methodological issue relies on the fact that the ani-
mals self-select their speed of gait. Indeed the measure-
ments give rise to comparisons of variables calculated
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Figure 2 Using principal component analysis (PCA) for the follow-up of individuals . The active individuals, used to define the plane, were
eight healthy adult dogs represented by empty circles, and eleven GRMD adult dogs represented by grey points. 94.53% of the total variance is
explained by the two first components, component 1 along the X axis and component 2 along the Y axis. The projection of the individuals on
the PCA plane following these components are represented in panels A to D, and the projection of the variables in panel E. The healthy and
GRMD dogs of the present study were used as supplementary individuals. Each GRMD dog is represented using his own symbol (see table 1).
The healthy growing dogs are represented by black points. A: projection of the 2 months-old dogs on the PCA plane; B: projection of the 4
months-old dogs on the PCA plane; C: projection of the 6 months-old dogs on the PCA plane; D: projection of the 9 months-old dogs on the
PCA plane. E: projection of the seven variables. The first component explains 72.61% of the total variance and is mainly explained by the stride
frequency, the stride length, the total power and the medio-lateral part of the power. The second component explains 21.92% of the total
variance and is mainly explained by the cranio-caudal and the dorso-ventral part of the power. F Evolution of the distance of each GRMD dog
from the centre of gravity of the six age-matched healthy controls. The grey zone represents the mean (grey line) ± 1SD (black lines) of this
distance in healthy dogs.
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Page 8 of 11from acceleration curves recorded over a wide range of
speeds and with three types of gait. However, to the
experience of teams working on GRMD dogs’ locomo-
tion [2,3], this wide range of speed abilities would pre-
cisely make a standardisation of speed very difficult, if
not impossible. As an example, if a standardized speed
had been considered, the lowest speed measured in
GRMD adults dogs, i.e. 0.26 m/s [3] should have been
chosen, to allow all the ambulant dogs to perform the
test. This protocol could not be retained as it is by far
artificial and devoid of clinical sense, to force all the
dogs to walk at this very low speed. Moreover, the habi-
tuation time required by the use of a treadmill on dogs
would also probably be significant, and delay the begin-
ning of the follow-up, which should be as early as possi-
ble, in a context of therapeutic trials. However, it is
undeniable that most of the studied variables are influ-
enced by the speed, and one may put forward that all
the modifications observed in GRMD dogs are only due
to speed decrease. The decreased relative force index
proves that this is not true. This index was created in
order to avoid bias due to different speeds on the total
power, by dividing it by the speed. It is interesting to
note that the evolution of this variable globally follows
the evolution of the total power, attesting to both the
variations of this variable and the differences with the
healthy population are not only due to differences in
speed of locomotion. Furthermore, the spontaneous
speed of gait is known to be of clinical significance
[14,15] and for this reason it represents a relevant mea-
sure in GRMD dogs. Finally, one may analyse this issue
of speed variations as a limitation, but we assume this
can be seen as an advantage as well, because of the clin-
ical pertinence provided by the self-selection of gait and
speed. With the same intention to quantitatively assess a
situation as spontaneous and physiological as possible,
the preferred and more comfortable gait was selected,
using the regularity index.
Attesting to the success of this process, the studied
variables were, in a vast majority, correlated to the
motor score, meaning that the degradation of the gait
measured by accelerometry corresponds to the observed
clinical evolution. In the same way as the clinical score,
the gait variables reveal different evolution types. How-
ever, the relative SD observed among the GRMD popu-
lation for the gait variables are larger than for the motor
score (data not shown). This observation supports the
argument for a higher sensitivity of the accelerometric
measurements variables than the motor score to
describe the dogs’ locomotion ability. Moreover, if the
motor score is a good index to quantify the general
shape of the dog, it remains a non-objective evaluation,
to use with caution, particularly in non double-blinded
studies. However, accelerometry is the first fully
objective and quantitative method of gait analysis, suc-
cessfully assessed in clinically evolving GRMD dogs.
One of the objectives of this study was to assess if a
longitudinal follow-up of one particular individual was
possible. Examining more closely the results obtained
dog per dog, different evolution profiles can be identi-
fied, allowing a quantitative description of the well-
described heterogeneity of the disease [1,7]. Notably, the
three dogs having lost locomotion before the age of six
months (Dchou, Dfois and Dsir) share the same charac-
teristics of evolution. Within few weeks, their gait vari-
ables reached values comparable to or worse than the
values of adult GRMD dogs. Thus, this disease-course
bound to result in loss of locomotion, is not only more
severe in outcome but also accelerated in its evolution.
Moreover, at the first test session at 2 months, the
values of stride frequency and of speed measured for
these three dogs were among the lowest. This last point
suggests that, as early as at the age of 2 months, their
gait is already more impaired than the one of dogs who
will not lose locomotion. Low stride frequency and
s p e e dv a l u e sa t2m o n t h sc o u l db ec o n s i d e r e da sp r o g -
nostic markers of poor outcome. The predictive value of
these biomarkers needs a validation study with more
animals. Concerning the 9 other dogs included in the
study, different evolution patterns were also identifiable,
in function of their capacity to perform a regular and
maintained high frequency “bunny hopping” gallop. This
“bunny hopping” gallop, also called bound, is used by
large size mammals in acceleration and deceleration
phases of a classical rotary gallop [16]. In the case of
GRMD dogs, the maintenance of bound, a primitive
high-frequency gait, could be an adaptive response to
muscle weakness, to produce more power using two
synchronized limbs, and avoiding a single limb weight
support [16]. Two dogs, Dbrouille and Dalton, exhibited
surprising evolution patterns. Indeed, after a period of
degradation, they tended to improve their gait. This
observation emphasizes the need to carefully interpret a
slight improvement of gait in an animal participating in
a treatment protocol.
In order to simplify the data interpretation, and
because of the multitude of variables of interest, we
applied the PCA multivariate exploratory method as a
tool to position each dog in comparison to the others
during time. We have chosen to project the puppies as
supplementary observations on the PCA plane defined
b yt h ee i g h th e a l t h ya n dt h e1 1G R M Da d u l td o g so f
our previous study [3]. This has allowed analyzing the
chronology of the relative trajectories of healthy and
GRMD groups, and locating and following each animal
at different ages on a reference PCA plane.
We proposed the use of the Euclidean distance from a
control age-matched group as an overall variable to
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and interpretation. This distance has already been
described and used as a gait analysis index in kinematic
studies [11,17]. Our results regarding the evolution of
this variable show that it can be used as a global gait
index during pre-clinical trials, to improve the readabil-
ity of the results.
Conclusion
This longitudinal study has allowed the description of
gait pattern evolutions in GRMD dogs at a time when
the disease becomes symptomatic, and has identified
quantifiable and sequentially impaired gait variables.
The ability of accelerometry to monitor gait evolution
in dogs during several months, and to quantitatively
reflect the heterogeneity of the disease with a good
sensitivity has been demonstrated. The PCA analysis
was proposed as a final data analysis method, making
the interpretation of multivariate data as simple as
their measure. Our study showed that a 3D-accelero-
metric gait analysis device is ready to be used as a
simple and reliable gait follow-up tool during pre-
clinical therapeutic trials, providing reliable biomar-
kers quantitatively showing the heterogeneity of the
canine GRMD disease, a characteristic to take into
account when evaluating this pre-clinical model, and
which represents another feature in common with
DMD.
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